Clinical trials: Chimeric Antigen Receptor T-cell Therapy
High-grade Glioma, WHO Grade Ⅳ Glioma
Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
This is a phase I, open-Label, single/multiple dose, dose-escalation study to evaluate the safety, tolerability and antitumor activity of anti-B7-H3 CAR-T cell injection (TX103) in subjects with recurrent or progressive Grade 4…
- Trial name
- NCT06482905
- Testing
- Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103
- Where
- 4 sites in United States, China
- Volunteers
- 52 people
- Sponsor
- Tcelltech Inc.
Neoplasms, Hematologic Neoplasms
Research Development（RD）13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7（CD7）+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML)
This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 CAR-T therapy for patients with CD7-positive relapsed or refractory T-ALL/LBL/AML, and to evaluate the…
- Conditions
- Neoplasms, Hematologic Neoplasms, Hematologic Diseases
- Trial name
- NCT05907603
- Testing
- RD13-02 cell infusion
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Kai Lin Xu，MD
CDH17-positive Advanced Malignant Solid Tumors
Anti-CDH17 CAR-T Cell Injection in Patients With CDH17-positive Advanced Malignant Solid Tumors
This is a single-arm, open-label, exploratory clinical study to evaluate the safety and preliminary efficacy of Anti-CDH17 CAR-T cell injection in patients with CDH17-positive advanced malignant solid tumors.
- Trial name
- NCT06501183
- Testing
- Anti-CDH17 CAR-T cells
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Shanghai Pudong Hospital
Lupus Nephritis, ANCA Associated Vasculitis
Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells
Lupus nephritis (LN) and ANCA-associated vasculitis are severe autoimmune diseases, which may lead to the death of patients, particularly when they are refractory to the conventional therapeutic agents.
- Trial name
- NCT06277427
- Testing
- PRG-1801 （CAR-T against BCMA）
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Lingli Dong
Diffuse Large B-cell Lymphoma
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research
A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma
- Trial name
- NCT05715606
- Testing
- Metabolically Armed CD19 CAR-T cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Anhui Provincial Hospital
Myasthenia Gravis
Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis
This study is a single-center, open-label, single-arm, dose-exploration study to evaluate the safety and preliminary effectiveness of CD19-BCMA CAR-T in the treatment of refractory, generalized myasthenia gravis.
- Trial name
- NCT06371040
- Testing
- CD19-BCMA Targeted CAR-T Dose 1, CD19-BCMA Targeted CAR-T Dose 2
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Ting Chang, MD
T Cell Lymphoma, T Cell Leukemia
Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells
Chimeric antigen receptor (CAR)-modified T cells targeted against CD19 have demonstrated unprecedented successes in treating patients with hematopoietic and lymphoid malignancies.
- Conditions
- T Cell Lymphoma, T Cell Leukemia, T-cell Acute Lymphoblastic Leukemia, T-Cell Lymphoma of CNS
- Trial name
- BAH246 (NCT06420076)
- Testing
- CD5/CD7 CAR-T
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Essen Biotech
Lymphoma
CAR-T Cell Induced Cardiac Dysfunction: A Prospective Study
In this observational, prospective study, patients affected by B-cell Lymphoma and candidate to chimeric antigen receptor-T (CAR-T) cell infusion will be evaluated at three timepoints to establish the rate of cardiac dysfunction…
- Trial name
- CARdio-Tox (NCT06106776)
- Testing
- Chimeric Antigen Receptor
- Volunteers
- 48 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
B-cell Non-Hodgkin Lymphoma
A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma
The aim of this study was to analyze the safety and efficacy of CD3-CD20 bispecific antibody-based therapy in combination with CD19-CAR-T cells for the treatment of relapsed and refractory B-cell Non-Hodgkin's （B-NHL） lymphoma.
- Trial name
- NCT06464185
- Testing
- Bispecific antibody-based combined with CAR-T cell therapy
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Autoimmune Diseases
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases
The goal of this study is to evaluate the safety and efficacy of CD19 CAR T cells in the treatment of Refractory Autoimmune Diseases
- Trial name
- NCT07161193
- Testing
- CD19 CAR-T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Multiple Myeloma Refractory, Multiple Myeloma in Relapse
A Phase 1 Dose-escalation and Expansion Study of In Vivo BCMA-CAR T Cell Therapy (VV169) in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1, first in human, study to evaluate the safety and the effects of in vivo BCMA-CAR T cell therapy (VV169) in patients with Multiple Myeloma that has been previously treated and has come back, or does not respond to…
- Trial name
- NCT07802717
- Testing
- VV169
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Vyriad, Inc.
B-cell Leukemia, B-Cell Lymphoma
CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy
Treatment of patients with B cell lymphoma or leukemia with two doses of CD19-targeting chimeric antigen receptor (CAR) T cells to evaluate for safety and efficacy.
- Trial name
- NCT03068416
- Testing
- CAR T cells
- Where
- Sweden
- Volunteers
- 24 people
- Sponsor
- Uppsala University
Leukemia, Myeloid, Acute(AML), Precursor Cell Lymphoblastic Leukemia-Lymphoma
CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial
Adult patients with refractory or relapsed CD123+ hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia, or blastic plasmocytoid dentritic cell neoplasm will be…
- Conditions
- Leukemia, Myeloid, Acute(AML), Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic Syndromes (MDS), Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Trial name
- UHKT-CAR123-01 (NCT06765876)
- Testing
- Autologous CAR123 T lymphocytes
- Where
- Czechia
- Volunteers
- 18 people
- Sponsor
- Institute of Hematology and Blood Transfusion, Czech Republic
Multiple Myeloma in Relapse, Myeloma Multiple
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
The goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractory multiple myeloma.
- Conditions
- Multiple Myeloma in Relapse, Myeloma Multiple, Multiple Myeloma Progression, Neoplasms by Histologic Type
- Trial name
- inMMyCAR (NCT07075185)
- Testing
- KLN-1010
- Where
- 11 sites in United States, Australia
- Volunteers
- 70 people
- Sponsor
- Kelonia Therapeutics, Inc.
Breast Cancer
Chimeric Antigen Receptor-Modified T Cells for Breast Cancer
The purpose of this study is to evaluate the safety and efficacy of HER2-CAR-T cell Infusion for advanced HER2 positive breast cancer.
- Trial name
- NCT02547961
- Testing
- HER-2-targeting CAR T Cells infusion
- Where
- China
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Diffuse Large B Cell Lymphoma, Follicular Lymphoma
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
Evaluation of the efficacy and safety of CD22-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of recurrent or refractory CD22 positive B cell acute lymphoblastic leukemia (B-ALL)
- Conditions
- Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Primary Cutaneous Follicle Centre Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Trial name
- NCT03999697
- Testing
- Autologous chimeric antigen receptor T cell transfusing agent targeting CD22
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Plasma Cell Leukemia
A Study of CT0596 in Plasma Cell Leukemia
This study is a single-arm, open-label, exploratory dose-escalation and dosefinding clinical trial to evaluate the safety, efficacy, cellular pharmacokinetics and pharmacodynamics of CT0596 cells in patients with PCL.
- Trial name
- NCT06988059
- Testing
- CAR-T cells Infusion chimeric antigen receptor T cells
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Hematopoietic/Lymphoid Cancer
Combination Transfer of αCD19-TCRz-41BB and αCD22-TCRz-41BB CAR-T Cells for B-cell Hematologic Malignancy
Clinical study of CD19 CAR-T in the treatment of blood and lymphatic system tumor has been achieved a breakthrough. The main solution in clinical research is to use CD19 CAR-T infusion alone.
- Trial name
- NCT02903810
- Testing
- Mixed CAR-T Transfer
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xuzhou Medical University
B Cell Malignancies
CD19/22 Bi-specific CAR-T Cell Therapy
The purpose of this study is to assess the feasibility, safety and efficacy of anti-CD19/22 bi-specific CAR-T cell therapy in patients with CD19 and/or CD22 positive B cell malignancies.
- Trial name
- NCT05432882
- Testing
- bi-4SCAR CD19/22 T cells
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Lymphoma, B-Cell, Neurotoxicity
Magnetic Resonance Imaging in Immune Effector Cell-Associated Neurotoxicity Syndrome
The treatment of large-cell B-cell lymphomas refractory to more than 2 lines of therapy has recently been revolutionized by the use of immunotherapies consisting of autologous genetically modified cells or CAR-T CELLS (chimeric…
- Trial name
- MR-ICANS (NCT05510596)
- Testing
- Magnetic Resonance Imaging with contrast injection, Blood withdrawal, Neuropsychological tests
- Where
- France
- Volunteers
- 25 people
- Sponsor
- University Hospital, Montpellier
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.